We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 25, 2021

Nivolumab and Stereotactic Body Radiotherapy in Patients With Metastatic RCC

European Urology


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
Eur Urol 2021 Sep 30;[EPub Ahead of Print], C Masini, C Iotti, U De Giorgi, RS Bellia, S Buti, F Salaroli, I Zampiva, R Mazzarotto, C Mucciarini, MG Vitale, A Bruni, F Lohr, G Procopio, O Caffo, F Nole, F Morelli, S Baier, C Buttigliero, P Ciammella, G Timon, E Fantinel, G Carlinfante, A Berselli, C Pinto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading